Vitex to Present at the Fourth Annual Needham Biotechnology Conference

Search Blogs that Mention this News Release
Click this link to view linked Bookmarking Services
Click this link to view linked Blogging Services
Vitex to Present at the Fourth Annual Needham Biotechnology Conference
    WATERTOWN, Mass., May 18 /PRNewswire-FirstCall/ -- V.I. Technologies, Inc.
(Nasdaq: VITX) ("Vitex" or "the Company"), a biotechnology company dedicated
to developing the next generation of anti-infective products, has been invited
to speak at the Fourth Annual Needham Biotechnology Conference, to be held at
The Palace Hotel in New York City on Wednesday, May 25, 2005. Vitex's
presentation is scheduled to begin that day at 2:00 p.m., Eastern Daylight
Time.  Dr. Samuel K. Ackerman, Chairman and CEO of Vitex, will present.
    A link to the live webcast of Vitex's presentation will be available on
the Company's Web site at http://www.vitechnologies.com.  The webcast link to
access a replay of the presentation will be archived and available through
Wednesday, June 1, 2005.

    About Vitex
    Vitex is developing the next generation of anti-infective products. The
Company is engaged in the discovery and development of small molecule oral
drugs for the treatment of HIV and other major human viral diseases. Vitex's
proprietary discovery technologies and lead therapeutic candidate PA-457 focus
on novel targets in the virus life cycle, including virus fusion and virus
maturation. The Company's separate INACTINE(TM) technology is designed to
inactivate a wide range of viruses, bacteria and parasites in blood products,
and has demonstrated its ability to remove prion proteins. The Company's
clinical development program for INACTINE(TM) has been suspended while the
Company continues to address issues relating to immune responses observed in
certain patients in Phase 3 clinical trials. For more information on Vitex,
please visit our web site at: http://www.vitechnologies.com.
    Except for the historical information contained herein, the matters
discussed are forward-looking statements made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. These
statements involve risks and uncertainties, such as the progress of clinical
development of PA-457 and the timing of results of clinical trials, the
execution of the Company's financing plans, the timely availability of new
products, the Company's ability to execute plans to resume its clinical trial
program for the INACTINE(TM) viral inactivation system for red blood cells,
market acceptance of the Company's products, the impacts of competitive
products and pricing, government regulation of the Company's products, the
Company's ability to complete product development collaborations and other
strategic transactions and other risks and uncertainties set forth in the
Company's filings with the Securities and Exchange Commission. These risks and
uncertainties could cause actual results to differ materially from any
forward-looking statements made herein.

    CONTACT:
     John R. Barr
     President
     617-926-1551
     john.barr@vitechnologies.com
SOURCE V.I. Technologies, Inc.
http://www.vitechnologies.com
CONTACT:
John R. Barr, President of Vitex,
+1-617-926-1551, john.barr@vitechnologies.com